| Literature DB >> 34222431 |
Guang-Xia Cui1, Zi-Jun Wang1, Jin Zhao1, Ping Gong1, Shuai-Hong Zhao1, Xiao-Xue Wang1, Wen-Pei Bai2, Yan Li3.
Abstract
BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) has shown promising results in improving the survival of ovarian cancer patients. Although the safety profiles of CRS-HIPEC exist, more attention should be paid to gastrointestinal complications, as the procedure involves a considerable proportion of bowel resection and anastomosis. AIM: To identify the risk factors for delayed gastric emptying in ovarian cancer treated with CRS-HIPEC.Entities:
Keywords: Complication; Cytoreductive surgery; Delayed gastric emptying; Hyperthermic intraperitoneal chemotherapy; Nasogastric tube; Ovarian cancer
Year: 2021 PMID: 34222431 PMCID: PMC8223831 DOI: 10.12998/wjcc.v9.i18.4644
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Patients data (n = 77)
|
|
|
| Age (yr, median and range) | 59 (35-75) |
| BMI (kg/m2, median and range) | 22.83 (13.8-33.98) |
| Concomitant disease, | |
| Diabetes mellitus | 8 (10) |
| High blood pressure | 16 (21) |
| History of chemotherapy (cycles, median and range) | 6 (0-25) |
| Pelvic surgical history, | 62 (81) |
| Serum CA-125 level (U/mL, median and range) | 277.2 (7.2-10001.0) |
| Primary/recurrent ovarian cancer, | |
| Primary | 32 (42) |
| Recurrent | 45 (58) |
| FIGO stage for primary ovarian cancer ( | |
| IIIB | 7 |
| IIIC | 4 |
| IVB | 21 |
| Histology, | |
| Serous | 55 (71) |
| Others | 22 (29) |
BMI: Body mass index.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy characteristics (n = 77)
|
|
|
| Operation time (minute, median and range) | 630 (280-960) |
| Intraoperative hemorrhage (mL, median and range) | 600 (50-5000) |
| Number of organs resected (median and range) | 2 (0-9) |
| Resected organs, | |
| Ascending colon | 18 (23) |
| Transverse colon | 4 (5) |
| Descending colon | 5 (6) |
| Sigmoid colon | 19 (25) |
| Total colon | 3 (4) |
| Stomach (partial) | 3 (4) |
| Small intestine (partial) | 13 (17) |
| Rectum | 46 (60) |
| Liver (partial) | 3 (4) |
| Spleen | 7 (9) |
| Pancreas (partial) | 1 (1) |
| Gallbladder | 8 (10) |
| Omentectomy, | 56 (73) |
| Urinary bladder, | 2 (3) |
| Number of bowel resection, | 53 (69) |
| PCI (median and range) | 16 (1-39) |
| CCS, | |
| CC 0-1 | 60 (78) |
| CC 2-3 | 17 (22) |
| Chemotherapeutic agent, | |
| Docetaxel | 4 (5) |
| Docetaxel + carboplatin | 55 (71) |
| Mitomycin + docetaxel | 4 (5) |
| Mitomycin + carboplatin | 14 (19) |
CC: Cytoreduction; CCS: Cytoreduction scoring; PCI: Peritoneal cancer index.
Univariate analysis of risk factors associated with delayed gastric emptying after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
|
|
|
|
|
| |
|
|
| ||||
| Age (yr) | 2.697 | 0.101 | |||
| ≥ 70 | 9 | 6 | 3 | ||
| < 70 | 68 | 22 | 46 | ||
| BMI (kg/m2) | 5.059 | 0.025 | |||
| ≥ 23 | 35 | 8 | 27 | ||
| < 23 | 42 | 20 | 22 | ||
| Pelvic surgery history | 4.498 | 0.034 | |||
| Yes | 62 | 19 | 43 | ||
| No | 15 | 9 | 6 | ||
| Comorbidity (DM/HBP) | 2.802 | 0.094 | |||
| Yes | 24 | 12 | 12 | ||
| No | 53 | 16 | 37 | ||
| History of chemotherapy | 4.334 | 0.037 | |||
| ≥ 7 cycles | 34 | 8 | 26 | ||
| < 7 cycles | 43 | 20 | 23 | ||
| CA-125 level | 0.990 | 0.320 | |||
| Normal (< 35 U/mL) | 12 | 2 | 10 | ||
| Elevated (≥ 35 U/mL) | 65 | 25 | 40 | ||
| Pleural effusion before surgery | 0.359 | 0.549 | |||
| Yes | 19 | 8 | 11 | ||
| No | 58 | 20 | 38 | ||
| PCI | 1.967 | 0.161 | |||
| ≥ 10 | 52 | 22 | 30 | ||
| < 10 | 14 | 2 | 12 | ||
| Diaphragmatic invasion | 0.717 | 0.397 | |||
| Yes | 23 | 10 | 13 | ||
| No | 54 | 18 | 36 | ||
| Perigastric and gastric dissection | 0.648 | 0.421 | |||
| Yes | 13 | 6 | 7 | ||
| No | 64 | 22 | 42 | ||
| Operation time | 4.827 | 0.047 | |||
| ≥ 7 h | 65 | 27 | 38 | ||
| 7 h | 12 | 1 | 11 | ||
| Intraoperative hemorrhage | 7.112 | 0.008 | |||
| ≥ 800 mL | 29 | 16 | 13 | ||
| < 800 mL | 48 | 12 | 36 | ||
| Anastomosis | 3.634 | 0.057 | |||
| Yes | 53 | 23 | 30 | ||
| No | 24 | 5 | 19 | ||
| Number of organs removed | 2.495 | 0.114 | |||
| ≥ 4 | 27 | 13 | 14 | ||
| < 4 | 50 | 15 | 35 | ||
| Pleural effusion after surgery | 3.667 | 0.056 | |||
| Yes | 44 | 20 | 24 | ||
| No | 33 | 8 | 25 | ||
DGE: Delayed gastric emptying; PCI: Peritoneal cancer index.
Multivariate analysis of risk factors associated with delayed gastric emptying after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
|
|
|
|
| |
|
|
| |||
| Age (yr) | ||||
| ≥ 70 | 7.127 | 1.122 | 45.264 | 0.037 |
| < 70 | 1 | |||
| Intraoperative hemorrhage | ||||
| ≥ 800 mL | 3.416 | 1.067 | 10.939 | 0.039 |
| < 800 mL | 1 | |||
| BMI (kg/m2) | ||||
| ≥ 23 | 0.450 | 0.147 | 1.379 | 0.162 |
| < 23 | 1 | |||
| Operation time | ||||
| ≥ 7 h | 3.206 | 0.329 | 31.226 | 0.316 |
| < 7 h | 1 | |||
| History of abdominal surgery | ||||
| Yes | 0.787 | 0.175 | 3.538 | 0.755 |
| No | 1 | |||
| History of chemotherapy | ||||
| ≥ 7 cycles | 0.301 | 0.078 | 1.167 | 0.082 |
| < 7 cycles | 1 | |||
BMI: Body mass index.